European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Receive
Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Receive| Merck & Co. (NYSE: MRK) | Delayed: 115.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $115.48 | 52 Week Low | $47.97 | |||
| Day High | $115.48 | P/E | 78.56 | |||
| Day Low | $115.48 | EPS | $1.47 | |||
| Volume | 12,902 | |||||
